Dr Pallavi Tiwari's work is based on recent clinical findings that 90% of the Glioblastoma Multiforme (GBM) recurrences occur close to the tumour margin, suggesting that malignant cells are present at the periphery of the tumour but are not visually discernible.
GBM is the most common and most aggressive cancer that begins within the brain.
"Less than 5% of all GBM patients live for more than five years," Tiwari, a leading cancer researcher working at Case Western Reserve University, said.
She said that despite several advances in drug discovery and clinical trials for cancer treatment, all GBM patients still follow the same 'one-fits-all' treatment regimen.
Tiwari, who is from Madhya Pradesh, presented her new research before at the Radiological Society of North America (RSNA) meeting recently.
"With Obama administration's push for personalised therapy, a pressing need in precision medicine is to identify patients with GBM who are suitable for specific clinical trials based on their tumour characterisation, instead of a 'one-size-fits-all' treatment," a media release said.
Unfortunately, this has not been feasible so far in the absence of reliable non-invasive and quantitative measurements regarding patient prognosis (likely outcome of the disease) in GBMs, Tiwari noted.
Recommended By Colombia
Tiwari and her team have shown on 62 patients that these computer-extracted features from tumour margins and its surrounding areas on MRI are together predictive of GBM outcomes, the press release said.
No comments:
Post a Comment